Tasimelteon significantly reduced sleep onset latency from the first night, with improvements maintained over 4 weeks in ...
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the publication of an article titled "Melatonin agonist ...
Long-Term Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Noninferiority Study Comparing Two Fractionation Schedules in Patients With Low-Risk Prostate Cancer This is a randomized, ...
RAPT on track to initiate trial this yearSOUTH SAN FRANCISCO, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical ...
Phase 3 study expected to enroll 6,000 participants starting in the Northern Hemisphere- Participants will include adults over 65 years of age ...
In early September, RemeGen announced the acceptance by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China of its Biologics License Application (BLA) ...
Abbvie (($ABBV)) announced an update on their ongoing clinical study. AbbVie is conducting a Phase 2 study titled A Phase 2, Multicenter, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback